公开(公告)号：EP1864660B1

公开(公告)日：2010-12-29

申请号：EP06077149.0

申请日：2002-11-01

申请人： Spectrum Pharmaceuticals, Inc.

发明人： Nuijen, Bastiaan ,  Pfadenhauer, Ernie ,  Beijen, Jos F.

IPC分类号： A61K31/404 ,  A61K47/10 ,  A61P13/10 ,  A61P35/00

CPC分类号： A61K9/19 ,  A61K9/0034 ,  A61K9/127 ,  A61K31/404 ,  Y10S514/908 ,  Y10S514/952 ,  Y10S514/97

公开(公告)号：EP1509243A4

公开(公告)日：2009-06-24

申请号：EP03756329

申请日：2003-06-02

申请人： TRANSDERMAL BIOTECHNOLOGY INC

发明人： PERRICONE NICHOLAS V DR

IPC分类号： A61K9/127 ,  A61K38/00 ,  A61K38/22 ,  A61K38/23 ,  A61K38/27 ,  A61K38/28 ,  A61K47/20 ,  A61K47/22 ,  A61K47/24

CPC分类号： A61K47/24 ,  A61J3/07 ,  A61K9/0014 ,  A61K9/02 ,  A61K9/06 ,  A61K9/127 ,  A61K9/1277 ,  A61K31/56 ,  A61K38/02 ,  A61K38/11 ,  A61K38/23 ,  A61K38/24 ,  A61K38/27 ,  A61K38/28 ,  A61K38/31 ,  A61K38/56 ,  A61K47/10 ,  A61K47/14 ,  A61K47/22 ,  A61K47/34 ,  C07K14/62 ,  Y10S514/806 ,  Y10S514/807 ,  Y10S514/808 ,  Y10S514/866 ,  Y10S514/97

摘要： The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.

公开(公告)号：EP2060259A1

公开(公告)日：2009-05-20

申请号：EP09075067.0

申请日：2002-11-01

申请人： Spectrum Pharmaceuticals, Inc.

发明人： Nuijen, Bastiaan ,  Pfadenhauer, Ernie ,  Beijen, Jos F.

IPC分类号： A61K31/404 ,  A61P13/10 ,  A61P35/00 ,  A61K9/00 ,  A61K47/10 ,  A61K9/08

CPC分类号： A61K9/19 ,  A61K9/0034 ,  A61K9/127 ,  A61K31/404 ,  Y10S514/908 ,  Y10S514/952 ,  Y10S514/97

摘要： An anti-cancer formulation comprising: 5-(1-azaridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9) and a buffered formulation vehicle comprising tert-butanol/water. There is also discloses a method of preparing a formulation comprising 5-(1-azaridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9), which method comprises preparing a formulation comprising 5-(1-azaridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9) and a buffered formulation vehicle comprising tert-butanol/water, and lyophilising the formulation to give a lyophilisate.

摘要翻译： 一种抗癌制剂，其包含：5-（1- azaridinyl）-3-（羟甲基）-2 - [（E）-3-羟基丙-1-烯基] -1-甲基-1H-吲哚-4,7-二酮 （EO9）和缓冲制剂车辆，包括叔丁醇/水中。 因此，存在制备制剂，其包含5-（1- azaridinyl）-3-（羟甲基）-2-一个松散盘法 - [（E）-3-羟基丙-1-烯基] -1-甲基-1H-吲哚-4- ，7-二酮（EO9）的方法，包括制备制剂，其包含5-（1- azaridinyl）-3-（羟甲基）-2 - [（E）-3-羟基丙-1-烯基] -1-甲基-1H- 吲哚-4,7-二酮（EO9）和缓冲制剂车辆，包括叔丁醇/水，和冻干制剂，得到冻干物。

公开(公告)号：EP1948159A2

公开(公告)日：2008-07-30

申请号：EP06836415.7

申请日：2006-10-20

申请人： GENTA INCORPORATED

发明人： JULIAN, Thomas N.

IPC分类号： A61K31/28

CPC分类号： C07C229/76 ,  C07C235/60 ,  Y10S424/06 ,  Y10S514/97

摘要： Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailability relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.

公开(公告)号：EP1864660A3

公开(公告)日：2008-04-23

申请号：EP06077149.0

申请日：2002-11-01

申请人： Spectrum Pharmaceuticals, Inc.

发明人： Nuijen, Bastiaan ,  Pfadenhauer, Ernie ,  Beijen, Jos F.

IPC分类号： A61K31/404 ,  A61P13/10 ,  A61P35/00

CPC分类号： A61K9/19 ,  A61K9/0034 ,  A61K9/127 ,  A61K31/404 ,  Y10S514/908 ,  Y10S514/952 ,  Y10S514/97

摘要： Anti-cancer coating compositions comprising 3-hydroxymethyl-5- aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (EO9) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition in the treatment of bladder cancer.

公开(公告)号：EP1880732A1

公开(公告)日：2008-01-23

申请号：EP07019169.7

申请日：1994-12-16

申请人： NPS Allelix Corp.

发明人： The designation of the inventor has not yet been filed

IPC分类号： A61K38/29 ,  A61K9/14 ,  A61K47/12 ,  A61K47/26

CPC分类号： A61K38/29 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/12 ,  A61K47/26 ,  Y10S514/97

摘要： Described herein are preparations containing parathyroid hormone that has been stabilized with an excipient and buffering agent. Preferred preparations incorporate human PTH(1-84), mannitol as excipient and citrate as buffering agent, and are incorporated in vials as a freeze-dried powder for reconstitution to treat osteoporosis.

摘要翻译： 本文描述了含有已用赋形剂和缓冲剂稳定的甲状旁腺激素的制剂。 优选的制剂包含人PTH（1-84），甘露醇作为赋形剂和柠檬酸盐作为缓冲剂，并且作为用于重建治疗骨质疏松症的冷冻干燥粉末掺入小瓶中。

公开(公告)号：EP1864660A2

公开(公告)日：2007-12-12

申请号：EP06077149.0

申请日：2002-11-01

申请人： Spectrum Pharmaceuticals, Inc.

发明人： Nuijen, Bastiaan ,  Pfadenhauer, Ernie ,  Beijen, Jos F.

IPC分类号： A61K31/404 ,  A61P13/10 ,  A61P35/00

CPC分类号： A61K9/19 ,  A61K9/0034 ,  A61K9/127 ,  A61K31/404 ,  Y10S514/908 ,  Y10S514/952 ,  Y10S514/97

摘要： Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (EO9) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

摘要翻译： 抗癌涂料组合物，包含3-羟基甲基-5-丙啶基1-1甲基-2- [1H-吲哚-4,7-二酮]丙烯醇（EO9）的游离缺失光盘。 更具体地，涂层组合物包括EO9和制剂车辆。 该制剂车辆改进了溶解性和EO9的稳定性。 此外，涂层组合物可以包括包衣剂的确在膀胱癌的治疗膀胱内递送该涂层组合物的过程中提供的涂料组合物对膀胱壁的更好的粘附性。

公开(公告)号：EP1602667B1

公开(公告)日：2007-04-04

申请号：EP05076848.0

申请日：1996-06-07

申请人： Novartis Vaccines and Diagnostics, Inc. ,  G.D. Searle & Co.

发明人： Dorin, Glenn J. ,  Arve, Bo H. ,  Pattison, Gregory L. ,  Halenbeck, Robert F. ,  Johnson, Kirk ,  Chen, Bao-Lu ,  Rana, Rajsharan K. ,  Hora, Maninder S. ,  Madani, Hassan ,  Gustafson, Mark E. ,  Tsang, Michael ,  Bild, Gary S. ,  Johnson, Gary V.

IPC分类号： C07K14/81 ,  C07K1/113 ,  A61K38/57 ,  A61K9/08 ,  A61K47/30

CPC分类号： C07K14/475 ,  A23L7/111 ,  A23L7/165 ,  A23L9/10 ,  A23L9/22 ,  A23L19/09 ,  A23L19/18 ,  A23L21/15 ,  A23L29/212 ,  A23L29/219 ,  A23P20/12 ,  A61K9/0019 ,  A61K9/08 ,  A61K38/57 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/36 ,  C07K1/1136 ,  C07K14/8114 ,  Y10S514/97 ,  Y10S514/973

公开(公告)号：EP0982990B1

公开(公告)日：2006-10-11

申请号：EP99906825.7

申请日：1999-02-05

申请人： Zila Nutraceuticals, Inc.

发明人： HEGENAUER, John, C.

IPC分类号： A01N43/08 ,  A61K31/27 ,  A23L1/302 ,  A61K31/375

CPC分类号： A61K9/08 ,  A23L33/15 ,  A23V2002/00 ,  A61K8/27 ,  A61K8/345 ,  A61K8/44 ,  A61K8/676 ,  A61K9/0014 ,  A61K9/0095 ,  A61K31/34 ,  A61K31/375 ,  A61K47/22 ,  A61K47/26 ,  A61Q19/00 ,  Y10S514/97 ,  A23V2250/708 ,  A23V2250/642 ,  A23V2250/1578 ,  A23V2250/1642 ,  A23V2250/30 ,  A23V2250/6406

摘要： Liquid vitamin C concentrate compositions comprise a mineral ascorbate and a pharmacologically acceptable liquid organic polyol solvent for the mineral ascorbate, the concentrate having a pH between about 5 and 7. The concentrate may also contain an aldonic compound and/or a pharmacologically acceptable zinc compound. The concentrate compositions are prepared by heating the solvent at 50-90 °C and mixing the ascorbate and/or aldonic compound and/or zinc compound into the heated solvent, preferably in the absence of oxygen. The concentrate compositions are also characterized as a composition which comprises the reaction product of a mineral ascorbate and a pharmacologically acceptable liquid organic polyol solvent and, optionally, an aldonic compound and/or a soluble non-toxic zinc compound, which reaction product includes 4-hydroxy-5-methyl-3(2H)-furanone and/or 3-hydroxy kojic acid. Finished vitamin C products, characterized by excellent long term vitamin C stability, are conveniently prepared by incorporating the concentrates into finished cosmetic, medical and food products.

公开(公告)号：EP0998942A4

公开(公告)日：2006-08-16

申请号：EP98900424

申请日：1998-01-19

申请人： JAPAN ENERGY CORP

发明人： FURUYA HIDEYUKI ,  MORITA HIROYUKI ,  TAKATSU YUKITAKA ,  MICHIBUCHI KOSE ,  TANIGAWA MAKOTO

IPC分类号： A61K9/19 ,  A61K38/58 ,  A61K47/12 ,  A61K47/26 ,  A61P7/02 ,  A61K9/14

CPC分类号： A61K9/19 ,  A61K38/58 ,  A61K47/12 ,  A61K47/26 ,  Y10S514/822 ,  Y10S514/97 ,  Y10S530/855

摘要： A method for elevating the stability of peptides containing the sequence -Asp-Gly- or -Asn-Gly- by preventing these sequences from changing into succinimide compounds or beta -transition compounds with the passage of time; and freeze-dried medicinal compositions containing hirudin, having excellent stability, and obtained by using the above method. The method comprises adding an organic acid to the solution of the above peptide to regulate the pH value of the solution to 5 to 6.5 followed by freeze-drying. As the peptide, use may be made of disulfite hirudin, hirudin variants, etc. It is also possible to add sucrose, mannitol, etc., together with the organic acid.